UBS O'Connor’s Turning Point Therapeutics TPTX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2022
Q3
– Sell
-775,000
Closed -$58.3M – 1063
2022
Q2
$58.3M Buy
+775,000
New +$34.4M 0.61% 28
2019
Q4
– Sell
-39,000
Closed -$1.47M – 380
2019
Q3
$1.47M Buy
+39,000
New +$1.7M 0.04% 189

UBS O'Connor's TPTX Position: Q3 2022 in Review

UBS O'Connor sold out of Turning Point Therapeutics (TPTX) in Q3 2022, closing a stake of 775,000 shares — an estimated $58.3M sold.

UBS O'Connor first reported a position in TPTX in Q3 2019 and held it in 2 quarters. The position peaked at $58.3M in Q2 2022. 0 funds tracked by Wall St. Rank hold TPTX as of Q3 2022.

  • UBS O'Connor reported no remaining Turning Point Therapeutics position as of Q3 2022 after selling out during the quarter.
  • UBS O'Connor sold 775,000 Turning Point Therapeutics shares in Q3 2022, an estimated $58.3M.
  • UBS O'Connor first reported a position in Turning Point Therapeutics in Q3 2019 and held it in 2 quarters.
  • UBS O'Connor's Turning Point Therapeutics position peaked at $58.3M in Q2 2022.
  • 0 funds tracked by Wall St. Rank held Turning Point Therapeutics as of Q3 2022.

Based on UBS O'Connor's 13F filing for Q3 2022, filed 14 Nov 2022.